Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00595790Phase 3Completed
Phase 3, randomised, single-blind trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (3 arms), sponsored by Valneva. Primary endpoint: Seroconversion Rate at Day 56. Started Sep 2005; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00595790.